Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Lynn Williams breaks NWSL goal
Lynn Williams scored her 79th league goal, becoming the National Women’s Soccer League all-time scor2024-05-21Israel raids main Gaza hospital as Rafah concerns grow
People inspect the damage in a room following Israeli bombardment at Nasser hospital in Khan Yunis i2024-05-21New Zealand reassessing proposed overhaul of Antarctic base
Scott Base in Antarctica. Photo: Antarctica New Zealand2024-05-21Government takes 'first steps' to speed up consent process
The "overly restrictive" resource management legislation was holding the country back, Chris Bishop2024-05-21Mohammad Mokhber: Who is Iran’s acting president?
DUBAI, United Arab Emirates (AP) — Iran’s first Vice President Mohammad Mokhber was appointed as act2024-05-21National and Labour defend Te Papa's right to display English version of Treaty of Waitangi
Neither National's deputy Nicola Willis nor Labour leader Chris Hipkins had a problem with Te Papa d2024-05-21
atest comment